首页 > 抗体蛋白 > 抗体
Brilliant Violet 605™ anti-mouse CD4 Antibod
产品名称:
Brilliant Violet 605™ anti-mouse CD4 Antibod
产品类别:
抗体
产品编号:
100451
产品应用:
100451
[价格]
规格 价格 库存
50µg ¥ 3708 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605? under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605? excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation.?Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin < 0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  13. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  2. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  3. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  4. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  5. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  6. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  7. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  8. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  9. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  10. Zhang X, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:494. PubMed
  11. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  12. Biancur DE, et al. 2020. Cell Metabolism. 33(1):199-210.e8. PubMed
  13. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  14. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  15. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  16. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  17. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  18. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  19. Liu CY, et al. 2020. Cell Rep. 33:108275. PubMed
  20. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  21. Wang Y, et al. 2020. Cell Death Dis. 1.169444444. PubMed
  22. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  23. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  24. Ullrich L, et al. 2021. Front Immunol. 12:729607. PubMed
  25. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  26. Shane HL, et al. 2020. Food Chem Toxicol. 136:111114. PubMed
  27. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  28. Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed
  29. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  30. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  31. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  32. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  33. Vazquez-Lombardi R, et al. 2017. Nat Commun. 8:15373. PubMed
  34. Rouse MD, et al. 2020. Front Microbiol. 11:414. PubMed
  35. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  36. Zhu G, et al. 2022. Front Microbiol. 12:806902. PubMed
  37. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  38. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  39. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  40. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  41. Rappaport AR, et al. 2022. Nat Commun. 13:3289. PubMed
  42. Goc J, et al. 2021. Cell. :. PubMed
  43. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
RRID
AB_2564591 (BioLegend Cat. No. 100451)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线